[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"minor-ischemic-stroke\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:minor-ischemic-stroke":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100617762","efficacy-and-safety-of-reperfusion-therapy-for-minor-ischemic-stroke-in-china-100617762",false,"NCT07322835","Efficacy and Safety of Reperfusion Therapy for Minor Ischemic Stroke in China","Efficacy and Safety of Reperfusion Therapy for Minor Ischemic Stroke in China: A Multicenter Prospective Cohort Study","Inclusion Criteria:\n\n1. Age \\>18 year\n2. Pre-stroke mRS ≤1\n3. Diagnosis of ischemic stroke, confirmed by imaging (CT or MRI)\n4. Stroke onset or last seen well (LSW) to visit ≤ 24h\n5. NIHSS ≤ 5\n6. Receive standard medication or IVT (TNK or rtPA) ± EVT, or EVT alone; for IVT beyond standard time window, initiation of treatment must occur within 4.5-24h of last seen well and ASPECTs≥7 or Perfusion lesion-ischemic core mismatch (ischemic core volume \\\u003C70mL, mismatch rate \\>1.2, mismatch volume \\>10mL or mismatch between the presence of an abnormal signal on DWI and no visible signal change on FLAIR)\n7. Patients or their eligible surrogates provided informed consent\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding women\n2. Patients who already received reperfusion therapy for the current stroke before arriving at the hospital\n3. Participation in another interventional clinical trial that could interfere with the outcomes of this study","ALL","18 Years",{"count":19,"type":20},5400,"ESTIMATED","OBSERVATIONAL","Acute ischemic stroke is the most common type of stroke in China, accounting for 69.6% -72.8% of new strokes. In recent years, the proportion of mild stroke (NIHSS ≤ 5 points) has gradually increased, exceeding 50%, and the recurrence rate of stroke within one year is 13.2%, with a mortality rate of 6.3%, and 4% -10% may experience early deterioration of neurological function within 72 hours. At present, the main treatment for mild ischemic stroke is antiplatelet aggregation or anticoagulation drugs, but there are still 10% -20% of patients with residual neurological disability. There is still controversy over whether acute reperfusion therapy (including intravenous thrombolysis and endovascular intervention therapy) can improve the prognosis of such patients. In addition, it has been confirmed that beyond the time window thrombolysis is effective for selected ischemic stroke patients, but it is urgent to clarify whether mild ischemic stroke patients can benefit from receiving beyond the time window thrombolysis. Due to the limited evidence and inconsistent conclusions on the efficacy and safety of reperfusion therapy in patients with mild stroke, it is urgent to have a deeper understanding of the current status of reperfusion therapy for mild ischemic stroke in China based on real clinical data, and systematically compare the efficacy and safety of reperfusion therapy (including intravenous thrombolysis and endovascular intervention therapy) with standard drug therapy for this type of patient. This project plans to conduct a nationwide multicenter prospective cohort study to evaluate the differences in excellent neurological function prognosis (mRS ≤ 1) and symptomatic intracranial hemorrhage rate among patients with mild ischemic stroke who receive reperfusion therapy (intravenous thrombolysis ± endovascular intervention therapy) compared to standard drug therapy at 90 days, in order to guide accurate clinical decision-making. The research results have significant implications for improving the prognosis of patients with mild ischemic stroke, and will also lay an important foundation for future large-scale randomized controlled studies to explore the optimal treatment strategies for mild stroke.",[24],"Minor Ischemic Stroke",[26,27,28,29],"minor ischemic stroke","reperfusion therapy","intravenous thrombolysis","endovascular therapy","NOT_YET_RECRUITING","2025-12-23",{"date":33,"type":34},"2026-01-07","ACTUAL",{"date":36,"type":20},"2026-01-01",{"date":38,"type":20},"2027-06-30",{"name":40,"class":41},"First Affiliated Hospital, Sun Yat-Sen University","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":42},"100547940","phase-3-teneteplase-reperfusion-therapy-in-acute-ischemic-cerebrovascular-events--100547940","NCT06414499","Teneteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-Ⅳ","TNK-tPA Treatment for Acute Minor Ischemic Stroke：A Randomized, Double-blind, Double-dummy Controlled Trial","TRACE Ⅳ","Inclusion Criteria\n\n1. Age ≥ 18 years;\n2. Onset-to-treatment time \\\u003C 4.5 h; onset time defined as \"last known well\" time;\n3. Clinical diagnosis of minor ischemic stroke (NIHSS ≤ 5) with persistent unilateral limb weakness or speech symptoms, defined as a score of ≥1 on either the language item or a single limb item of the NIHSS;\n4. Pre-stroke mRS 0-1;\n5. Informed consent signed.\n\nExclusion Criteria\n\n1. Planned or likely acute endovascular treatments before randomization;\n2. NIHSS 1a \\> 2;\n3. Known allergic to rhTNK-tPA;\n4. History of intracranial hemorrhage;\n5. Severe head trauma or previous stroke within 3 months；\n6. Intracranial or spinal surgery within 3 months;\n7. Gastrointestinal or urinary tract hemorrhage within 3 weeks；\n8. Major surgery within 2 weeks;\n9. Arterial puncture at a non-compressible site within 1 week；\n10. Intracranial tumors (excluding neuroectodermal tumors, e.g., meningiomas), large intracranial aneurysms, or arteriovenous malformations；\n11. Intracranial hemorrhage, including intraparenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, and subdural\u002Fepidural hematoma;\n12. Active visceral bleeding;\n13. Concomitantaortic arch dissection;\n14. Acute bleeding tendency, including platelet count \\\u003C100×10⁹\u002FL or other clinically significant conditions;\n15. Uncontrolled hypertension after active antihypertensive treatment: systolic blood pressure \\>180 mm Hg or diastolic \\>100 mm Hg;\n16. Blood glucose \\\u003C 2.8 or \\> 22.2 mmol \u002F L;\n17. Prior anticoagulant therapy, such as oral warfarin, with an INR \\>1.7 or PT \\>15 seconds;\n18. Use of heparin within 24 hours;\n19. Use of thrombin inhibitors or factor Xa inhibitors within 48 hours;\n20. Large cerebral infarction on head CT or MRI (infarction area \\>1\u002F3 of the middle cerebral artery territory);\n21. Todd's paralysis after a seizure or other neurological\u002Fpsychiatric disorders affecting cooperation;\n22. Severe, uncontrolled infections (e.g., acute pericarditis, infective endocarditis, or acute pancreatitis);\n23. Pregnant or breastfeeding women, or women unwilling to use effective contraception during the study period;\n24. Participation in another clinical trial within 3 months prior to screening;\n25. Other severe illnesses with a life expectancy of less than six months;\n26. Deemed unsuitable for the study or at increased risk by the investigator's judgment.",{"count":52,"type":20},1386,"INTERVENTIONAL",[55],"PHASE3","The purpose of this study is to evaluate the efficacy and safety of intravenous tenecteplase (0.25 mg\u002Fkg) compared with standard therapy in patients with acute ischemic stroke presenting with mild symptoms-defined as a National Institutes of Health Stroke Scale (NIHSS) score ≤5 accompanied by persistent unilateral limb weakness or speech impairment within 4.5 hours of onset.",[24],[59,60],"minor stroke","tenecteplase","RECRUITING","2025-07-20",{"date":64,"type":34},"2025-07-24",{"date":66,"type":34},"2025-07-09",{"date":68,"type":20},"2026-10-31",{"name":70,"class":41},"Beijing Tiantan Hospital"]